The class of medications known as Janus kinase inhibitors block cytokine-mediated
signaling via the Janus kinase-signal transducer and activator of transcription (JAK-STAT) …

Janus kinase inhibitors, also commonly referred to as JAK inhibitors, are a novel drug class
that target and block cytokine signaling mediated by the Janus kinase-signal transducer and …

Janus kinase family (JAKs) has recently attracted the attention of many researchers, and
several JAK inhibitor drugs have been developed targeting different members of the JAK …

Background: Tofacitinib (formerly known as CP-690,550, CP690550, tasocitinib), a novel
selective immunosuppressant, is a small molecule classified as Janus kinase inhibitor. The …

Cytokines are key mediators of the development and homeostasis of haematopoietic cells,
critical for host defense, but also for the development of autoimmune and inflammatory …

Janus kinases inhibitors are molecules that target Janus kinases—signal transducers and
activators of transcription (JAK/STAT). They inhibit this intracellular signal pathway, blocking …

Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a
spectrum of burdensome dermatologic conditions. The US Food and Drug Administration …

Objectives To record and summarize the overall efficacy and safety of JAKi in various
autoimmune conditions such as alopecia areata (AA), psoriasis vulgaris (PV), psoriatic …

The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway
is a ubiquitous intracellular signaling network. Selective JAK-inhibitors have anti …

Janus kinase (JAK) pathways are key mediators in the immunopathogenesis of psoriasis.
Psoriasis treatment has evolved with the advent of targeted therapies, which inhibit specific …